236 related articles for article (PubMed ID: 29178616)
1. Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Amornsiripanitch N; Nguyen VT; Rahbar H; Hippe DS; Gadi VK; Rendi MH; Partridge SC
J Magn Reson Imaging; 2018 Jul; 48(1):226-236. PubMed ID: 29178616
[TBL] [Abstract][Full Text] [Related]
2. Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
Thakur SB; Durando M; Milans S; Cho GY; Gennaro L; Sutton EJ; Giri D; Morris EA
J Magn Reson Imaging; 2018 Feb; 47(2):401-409. PubMed ID: 28640531
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
Kim JY; Kim JJ; Hwangbo L; Lee JW; Lee NK; Nam KJ; Choo KS; Kang T; Park H; Son Y; Grimm R
Eur Radiol; 2020 Jan; 30(1):66-76. PubMed ID: 31385051
[TBL] [Abstract][Full Text] [Related]
4. The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?
Roknsharifi S; Fishman MDC; Agarwal MD; Brook A; Kharbanda V; Dialani V
Acad Radiol; 2019 Jul; 26(7):923-929. PubMed ID: 30293819
[TBL] [Abstract][Full Text] [Related]
5. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
[TBL] [Abstract][Full Text] [Related]
6. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
7. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
8. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
Horvat JV; Bernard-Davila B; Helbich TH; Zhang M; Morris EA; Thakur SB; Ochoa-Albiztegui RE; Leithner D; Marino MA; Baltzer PA; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
J Magn Reson Imaging; 2019 Sep; 50(3):836-846. PubMed ID: 30811717
[TBL] [Abstract][Full Text] [Related]
9. Support vector machine for breast cancer classification using diffusion-weighted MRI histogram features: Preliminary study.
Vidić I; Egnell L; Jerome NP; Teruel JR; Sjøbakk TE; Østlie A; Fjøsne HE; Bathen TF; Goa PE
J Magn Reson Imaging; 2018 May; 47(5):1205-1216. PubMed ID: 29044896
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER+/HER2- Breast Cancer Quantified With 21-Gene Recurrence Score.
Chen Y; Tang W; Liu W; Li R; Wang Q; Shen X; Gong J; Gu Y; Peng W
J Magn Reson Imaging; 2023 Aug; 58(2):444-453. PubMed ID: 36440706
[TBL] [Abstract][Full Text] [Related]
11. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status.
Shin JK; Kim JY
J Magn Reson Imaging; 2017 Jan; 45(1):94-102. PubMed ID: 27313102
[TBL] [Abstract][Full Text] [Related]
13. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
14. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
Newitt DC; Zhang Z; Gibbs JE; Partridge SC; Chenevert TL; Rosen MA; Bolan PJ; Marques HS; Aliu S; Li W; Cimino L; Joe BN; Umphrey H; Ojeda-Fournier H; Dogan B; Oh K; Abe H; Drukteinis J; Esserman LJ; Hylton NM;
J Magn Reson Imaging; 2019 Jun; 49(6):1617-1628. PubMed ID: 30350329
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
16. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
17. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
18. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy.
Zhang M; Horvat JV; Bernard-Davila B; Marino MA; Leithner D; Ochoa-Albiztegui RE; Helbich TH; Morris EA; Thakur S; Pinker K
J Magn Reson Imaging; 2019 Mar; 49(3):864-874. PubMed ID: 30375702
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric diffusion-weighted imaging in breast lesions: Association with pathologic diagnosis and prognostic factors.
Suo S; Cheng F; Cao M; Kang J; Wang M; Hua J; Hua X; Li L; Lu Q; Liu J; Xu J
J Magn Reson Imaging; 2017 Sep; 46(3):740-750. PubMed ID: 28139036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
